Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 6/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27378399 | 1.00 | FKBP1A (0.42) | FKBP1ALTA4HNPC1RAB9ABACE1 | |
| SCHEMBL27379476 | 0.89 | FKBP1A (0.43) | FKBP1ALTA4HNPC1RAB9ABACE1 | |
| SCHEMBL3452265 | 0.84 | ALDH1A1 (0.43) | FKBP1ABACE1ALDH1A1GAA | |
| SCHEMBL29671561 | 0.81 | FKBP1A (0.47) | FKBP1ALTA4HBACE1KMT2AALDH1A1 | |
| SCHEMBL27551310 | 0.81 | FKBP1A (0.47) | FKBP1ALTA4HBACE1KMT2AALDH1A1 | |
| SCHEMBL13310419 | 0.80 | ALDH1A1 (0.47) | BACE1ALDH1A1GAA | |
| SCHEMBL13310423 | 0.80 | ALDH1A1 (0.47) | BACE1ALDH1A1GAA | |
| SCHEMBL3909608 | 0.78 | SCN9A (0.43) | LTA4HBACE1GAA | |
| SCHEMBL3909612 | 0.78 | SCN9A (0.43) | LTA4HBACE1GAA | |
| SCHEMBL29035348 | 0.76 | SCN9A (0.48) | FKBP1ALTA4HBACE1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | FKBP1A 1060/4885LTA4H 4444/4885NPC1 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.